1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
Book a demo
-
  1. My Preqin
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
  1. My Preqin
Book a demo

Shandong Sito Bio-technology Co., Ltd.

Have updates for this profile?  Please contribute data

About Deals
= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2010

Location

Heze Shandong China

Primary Industry

Biotechnology

About

Established in 2010 and based in Heze, China, Shandong Sito Bio-technology Co., Ltd operates as a biopharmaceutical company, specializing in microbial control agents and APIs. It has passed ISO14000 environmental management system, ISO18000 safety and health management system, and ISO50001 energy management system certifications. In July 2014, the company set up a subsidiary with Zhejiang Xianju Pharmaceutical. In January 2021, it was listed on the Shenzhen Stock Exchange. In October 2023, Sito Bio-technology announced to acquire Yingu Pharmaceutical. Sito Bio-technology specializes in the development and production of key intermediates and APIs for microbial control agents and novel steroid hormone drugs. Its main products include 17α-hydroxyprogesterone acetate, 17α-hydroxyprogesterone, and 17α-hydroxyprogesterone acetate. The company's revenue and net income for 2022 were CNY 1.31 billion and CNY 42 million, respectively.
Current Investors
China Asset Management, Lord Abbett China Asset Management Co.,ltd., Qingdao Fanyi Asset Management Co., Ltd.

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.sitobiotech.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only

Deals

Deals Type
Add-on, LP Direct
PIPE
Trade Sale
Deal Status Target (s) Deal Date Investor(s) Seller(s) Deal size (Mn) Enterprise value (Mn) Post-money valuation (Mn) EBITDA multiple (x) Revenue multiple (x) Lead partner (s)
Announced Yingu Pharmaceutical 16 Oct 2023
Completed Shandong Sito Bio-technology Co., Ltd. 18 Apr 2023
Completed Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA 01 Jul 2019
Displaying 1-3 of 3

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.
Sign in Request demo